TendieTensor TendieTensor
You’re browsing as
Guest
Free Preview
Sign in/sign up to unlock all features.

News  ›  GlobeNewswire Inc.

MoonLake Immunotherapeutics (MLTX) Faces Securities Class Action After Company Reported Disastrous Phase 3 Trial Data For Sole Drug Candidate -- Hagens Berman

GlobeNewswire Inc. Logo GlobeNewswire Inc. By Hagens Berman
MoonLake Immunotherapeutics (MLTX) Faces Securities Class Action After Company Reported Disastrous Phase 3 Trial Data For Sole Drug Candidate -- Hagens Berman

MoonLake Immunotherapeutics faces a securities class action lawsuit after reporting disappointing Phase 3 trial results for its sole drug candidate sonelokimab, causing a 90% stock price drop and allegations of misleading investors about the drug's potential.

Insights
SYK   neutral

Mentioned as a key player without specific growth or performance details


MLTX   negative

Stock price dropped 90% after failed Phase 3 trial, facing lawsuit for allegedly misleading investors about drug candidate's efficacy and potential